Related Experiment Video
Updated: Jul 16, 2026

High Content Screening Analysis to Evaluate the Toxicological Effects of Harmful and Potentially Harmful Constituents (HPHC)
Published on: May 10, 2016
An evaluation of the safety of Crodamol PMP
B K Bernard1, J E Harris, J E Fischer
1SRA International, Inc., Washington, DC, USA.
Abstract:
Crodamol PMP (polyoxypropylene (2) myristyl ether propionate) has been extensively employed for many years in a wide variety of human cosmetics in the absence of reported adverse reactions. The compound is being considered for use as a vehicle for veterinary pharmaceuticals in food-producing animals. This paper reviews information on the chemistry, metabolism, and toxicity of this compound, including the details of a recently completed multi-dose study in rats. Based upon this information, it is concluded that Crodamol PMP is a substance of apparently low toxic potential. Potential new uses of this compound must compare the likely exposure to the substance with the available toxicity information.
More Related Videos
Related Concept Videos
Methods of Documentation II: POMR
Drug Regulation
Pharmacovigilance
This process, termed pharmacovigilance, aims to detect, evaluate, and minimize harmful effects related to medication use. The data collection for pharmacovigilance depends on spontaneous reporting systems, where healthcare professionals or patients voluntarily report suspected ADRs.
In some cases, there...
Analgesia and Pain Management
Therapeutic Drug Monitoring: Drug Analysis Methods
Impact of Pharmacokinetic–Pharmacodynamic Models: Regulatory Decisions

